medigraphic.com

2003, Number 1

<< Back Next >>

Enf Infec Microbiol 2003; 23 (1)

Schemata of antiretroviral therapy recommended for patients without previous treatment

Language: Spanish
References: 39
Page: 5-16
PDF size: 90.24 Kb.


Text Extraction

No abstract


REFERENCES

  1. Benson CA, Deeks SG, Brun SC et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002;185:599-607.

  2. British HIV Association. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 2001;10:76-111.

  3. Cameron DW, Japour AJ, Xu Y et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999;13:213-224.

  4. Carpenter CC, Cooper DA, Fischl MA et al. Antiretroviral therapy for HIV infection in adults. JAMA 2000;283:381-390.

  5. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.

  6. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.

  7. Chaisson RE, Keruly JC, Moore RD. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA 2000;284:3128-3129.

  8. Eron Jr J, Murphy RL, Peterson D et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of Thymidine Analog Regimen Therapy (START II). AIDS 2000;14:1601-1610.

  9. Fletcher CV, Acosta EP, Cheng H et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects. AIDS 2000;14:2495-2501.

  10. Flexner C. Dual protease inhibitor therapy in HIV-infected patients. Annu Rev Pharmacol Toxicol 2000;40:649-674.

  11. Glesby MJ, Hoover DR, Vaamonde CM. Osteonecrosis in patients infected with human immunodeficiency virus. J Infect Dis 2001;184:519-523.

  12. Hogg RS, Yip B, Chan KJ et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-2577.

  13. Hogg RS, Heath KV, Yip B et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-454.

  14. Kaplan J, Hanson D, Karon J et al. Late initiation of antiretroviral therapy (at CD4+ lymphocyte count < 200 cells/µL) is associated with increased risk of death. From: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract 520.

  15. Kemper CA, Witt MD, Keiser PH et al. Sequencing of protease inhibitor therapy. AIDS 2001;15:609-615.

  16. Kempf DJ, Rode RA, Xu Y et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998;12:F9-F14.

  17. King M, Bernstein B, Kempf D et al. Comparison of time to achieve HIV RNA < 400 copies/mL and < 50 copies/mL in a phase III, blinded, randomized clinical trial of ABT-378/r vs NFV in ARV-naive patients. From: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract 329.

  18. Knobel H, Guelar A, Valdecillo G et al. Osteopenia in HIV-infected patients. From: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract 629.

  19. Kurowski M, Kaeser B, Mroziekiewicz A et al. The influence of low doses of ritonavir on the pharmacokinetics of nelfinavir 1,250 mg BID. From: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Canada. Abstract 1639.

  20. Li TS, Tubiana R, Katlama C et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-1686.

  21. Lonergan JT, Behling C, Pfander H et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000;31:162-166.

  22. Meyer D, Behrens G, Schneider A et al. Serum lactate in nucleoside analogue treated HIV patients correlates with serum-lipids [abstract]. Antivir Ther 2000;5(Suppl. 5):54. Abstract P52.

  23. Mulligan K, Grunfeld C, Tai VW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV-1 infection. J Acquir Immune Defic Syndr 2000;23:35-43.

  24. Murphy RL, Brun S, Hicks C et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection. AIDS 2001;15:F1-F9.

  25. Murphy RL, Katlama C, Johnson V et al. The Atlantic study. From: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract LB-22.

  26. Opravil M, Ledergerber B, Furrer H et al. Clinical benefit of early initiation of HAART in patients with asymptomatic HIV infection and CD4 counts > 350/mm3. From: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract LB6.

  27. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.

  28. Phillips AN, Staszewski S, Weber R et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001;286:2560-2567.

  29. Podzamczer D, Ferrer E, Consiglio E et al. Final 12-month results from the COMBINE study. From: 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; July 7-11, 2001; Buenos Aires, Argentina. Abstract 7.

  30. Rizzardi GP, de Boer RJ, Hoover S et al. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest. 2000;105:777-782.

  31. Robbins G, Shafer R, Smeaton L et al. Antiretroviral strategies in naive HIV+ subjects: comparisons of sequential 3-drug regimens (ACTG 384). Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract LbOr20A.

  32. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-1873.

  33. Staszewski S, Keiser P, Montaner J et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults. JAMA 2001;285:1155-1163.

  34. Staszewski S. Update on study 006-EFV + AZT + 3TC versus the current ‘standard of care’ IDV + AZT + 3TC. Int J Clin Pract Suppl. 1999;103:10-15.

  35. Sterling TR, Chaisson RE, Bartlett JG et al. CD4+ lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART. From: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Ill. Abstract 519.

  36. Tebas P, Powderly WG, Claxton S et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63-F67.

  37. US Public Health Service. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Updated February 4, 2002. Disponible en: http://www.hivatis.org/trtgdlns.html#Adult

  38. Yeni PG, Hammer SM, Carpenter CCJ et al. Antiretroviral Treatment for Adult HIV Infection in 2002. Updated Recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-235.

  39. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: Guidelines for a public health approach. Abril 2002.




2020     |     www.medigraphic.com